Loading institutional data...
Loading institutional data...
Held by 400 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $86.66 today, the market must believe free cash flow compounds 6.8%/yr for a decade (off $134M normalized FCF).
2-stage DCF · 0.03B shares · net debt -$478M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $134M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 8 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 39%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 8 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~137.8% on $10M of debt.
Cash of $488M fully covers short-term debt of $10M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 6-yr range · 17th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 6-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 5.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 55.9 | 41.3 | 35.1 | 30.1 | 30.2 | 36.2 | 40.6 | 40.1 |
| Gross Profit | 44.1 | 58.7 | 64.9 | 69.9 | 69.8 | 63.8 | 59.4 | 59.9 |
| R&D | 104.9 | 84.2 | 73.4 | 73.7 | 28.7 | 14.9 | 12.7 | 11.4 |
| SG&A | 94.6 | 100.0 | 94.3 | 126.5 | 74.8 | 49.5 | 38.2 | 30.6 |
| Operating Income | -155.5 | -125.4 | -102.9 | -130.3 | -33.6 | -11.9 | 8.5 | 17.9 |
| Income Tax | 0.0 | 0.0 | 0.0 | — | 0.1 | -0.7 | 0.1 | -13.7 |
| Net Income | 182.8 | -141.9 | -112.1 | -146.1 | -38.7 | -10.3 | 8.0 | 31.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on TMDX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $605.5M 100.0% | $441.5M 100.0% | $241.6M 100.0% | $93.5M 100.0% | $30.3M 100.0% | $25.6M 100.0% | $23.6M 100.0% | $13.0M 100.0% |
| Cost of Revenue | $242.7M 40.1% | $179.5M 40.6% | $87.5M 36.2% | $28.2M 30.2% | $9.1M 30.1% | $9.0M 35.1% | $9.7M 41.3% | $7.3M 55.9% |
| Gross Profit | $362.8M 59.9% | $262.1M 59.4% | $154.1M 63.8% | $65.3M 69.8% | $21.2M 69.9% | $16.6M 64.9% | $13.9M 58.7% | $5.7M 44.1% |
| Research & Development | $69.1M 11.4% | $56.0M 12.7% | $36.1M 14.9% | $26.8M 28.7% | $22.3M 73.7% | $18.8M 73.4% | $19.9M 84.2% | $13.7M 104.9% |
| Selling, General & Admin | $185.2M 30.6% | $168.6M 38.2% | $119.6M 49.5% | $69.9M 74.8% | $38.3M 126.5% | $24.2M 94.3% | $23.6M 100.0% | $12.3M 94.6% |
| Total Operating Expenses | $254.2M 42.0% | $224.6M 50.9% | $182.8M 75.7% | $96.7M 103.5% | $60.6M 200.2% | $43.0M 167.8% | $43.5M 184.1% | $26.0M 199.5% |
| Operating Income | $108.6M 17.9% | $37.5M 8.5% | -$28.7M -11.9% | -$31.4M -33.6% | -$39.4M -130.3% | -$26.4M -102.9% | -$29.6M -125.4% | -$20.2M -155.5% |
| Interest Expense | $13.8M 2.3% | $14.4M 3.3% | $10.8M 4.5% | $3.7M 4.0% | $3.9M 12.8% | $4.0M 15.5% | $4.4M 18.4% | $2.7M 20.9% |
| Other Income (Expense), net | -$1.1M -0.2% | -$1.7M -0.4% | $2.1M 0.9% | -$4.7M -5.1% | -$4.8M -15.7% | -$2.3M -9.1% | -$3.9M -16.5% | -$3.5M -26.7% |
| Pretax Income | $107.5M 17.8% | $35.8M 8.1% | -$26.7M -11.0% | -$36.2M -38.7% | -$44.2M -146.0% | -$28.7M -112.0% | -$33.5M -142.0% | -$23.7M -182.2% |
| Income Tax Expense | -$82.8M -13.7% | $316K 0.1% | -$1.6M -0.7% | $66K 0.1% | — | $0 0.0% | $0 0.0% | $0 0.0% |
| Net Income | $190.3M 31.4% | $35.5M 8.0% | -$25.0M -10.3% | -$36.2M -38.7% | -$44.2M -146.1% | -$28.7M -112.1% | -$33.5M -141.9% | $23.8M 182.8% |
| Per Share | ||||||||
| EPS (Basic) | $5.60 | $1.07 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | — | — |
| EPS (Diluted) | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | — | — |
| Weighted Avg Shares (Basic) | 34.0M | 33.2M | 32.5M | 29.6M | 27.6M | 24.7M | — | — |
| Weighted Avg Shares (Diluted) | 40.5M | 35.2M | 32.5M | 29.6M | 27.6M | 24.7M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| TMDX | $3.0B | 17.8× | 18.4× | 4.9× | 37.1% | 59.9% | 31.4% | 40.2% | 39.4% | 0.1× | 400 |
Peers = companies sharing TMDX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.